Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance

被引：20

作者：

Balch, Curt ^{[1
,2
]}

Nephew, Kenneth P. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Indiana Univ Sch Med, Bloomington, IN 47405 USA

[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA

[3] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA

[4] Indiana Univ Sch Med, Dept Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA

[5] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Med Sci Program, Bloomington, IN 47405 USA

来源：

EPIGENETIC ALTERATIONS IN ONCOGENESIS | 2013年 / 754卷

基金：

美国国家卫生研究院;

关键词：

HISTONE DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR GENES; SUBEROYLANILIDE HYDROXAMIC ACID; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; BREAST-CANCER CELLS; DNA-HYPOMETHYLATING AGENT; ACUTE MYELOID-LEUKEMIA; PHASE-II TRIAL; EPITHELIAL OVARIAN-CANCER; CISPLATIN PLUS DECITABINE;

D O I：

10.1007/978-1-4419-9967-2_14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of "stemness" signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.

引用

页码：285 / 311

页数：27

共 220 条

[1] Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells [J].

Abbosh, Phillip H. ;

Montgomery, John S. ;

Starkey, Jason A. ;

Novotny, Milos ;

Zuhowski, Eleanor G. ;

Egorin, Merrill J. ;

Moseman, Annie P. ;

Golas, Adam ;

Brannon, Kate M. ;

Balch, Curtis ;

Huang, Tim H. M. ;

Nephew, Kenneth P. .

CANCER RESEARCH, 2006, 66 (11) :5582-5591

[2] Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer [J].

Aguilera, O. ;

Fraga, M. F. ;

Ballestar, E. ;

Paz, M. F. ;

Herranz, M. ;

Espada, J. ;

Garcia, J. M. ;

Munoz, A. ;

Esteller, M. ;

Gonzalez-Sancho, J. M. .

ONCOGENE, 2006, 25 (29) :4116-4121

[3] Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4 [J].

Ahn, Mee Young ;

Chung, Hae Young ;

Choi, Wahn Soo ;

Lee, Byung Mu ;

Yoon, Sungpil ;

Kim, Hyung Sik .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) :125-131

[4] Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo [J].

Alcazar, Oscar ;

Achberger, Susan ;

Aldrich, Wayne ;

Hu, Zhenbo ;

Negrotto, Soledad ;

Saunthararajah, Yogen ;

Triozzi, Pierre .

INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (01) :18-29

[5]

ANZAI H, 1992, CANCER RES, V52, P2180

[6] Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors [J].

Appleton, Kim ;

Mackay, Helen J. ;

Judson, Ian ;

Plumb, Jane A. ;

McCormick, Carol ;

Strathdee, Gordon ;

Lee, Chooi ;

Barrett, Sophie ;

Reade, Sarah ;

Jadayel, Dalal ;

Tang, Adrian ;

Bellenger, Katharine ;

Mackay, Lynsay ;

Setanoians, Albert ;

Schaetzlein, Andreas ;

Twelves, Chris ;

Kaye, Stanley B. ;

Brown, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4603-4609

[7] Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics [J].

Arzenani, Mohsen Karimi ;

Zade, Atosa Esteki ;

Ming, Yu ;

Vijverberg, Susanne J. H. ;

Zhang, Zhe ;

Khan, Zahidul ;

Sadique, Syed ;

Kallenbach, Lorenz ;

Hu, LiFu ;

Vukojevic, Vladana ;

Ekstrom, Tomas J. .

MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (19) :4119-4128

[8]

AVRAMIS VI, 1989, CANCER CHEMOTH PHARM, V24, P203

[9] Antimitogenic and chernosensitizing effects of the methylation inhibitor zebularine in ovarian cancer [J].

Balch, C ;

Yan, P ;

Craft, T ;

Young, S ;

Skalnik, DG ;

Huang, THM ;

Nephew, KP .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (10) :1505-1514

[10] New anti-cancer strategies: Epigenetic therapies and biomarkers [J].

Balch, C ;

Montgomery, JS ;

Paik, HI ;

Kim, S ;

Huang, THM ;

Nephew, KP .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :1897-1931

← 1 2 3 4 5 6 7 8 9 10 →